Novartis — Cryptosporidiosis Challenge Trial

[Scientific Research] Open Philanthropy recommended a grant of $2,500,000 over two years to Novartis to support a Phase IIa challenge trial of a new drug, ED1048, for the treatment of cryptosporidiosis. Cryptosporidiosis is caused by the Cryptosporidium parasite. The parasite is widespread globally and highly resistant to sanitizers used for cleaning drinking water. The disease can be fatal in small children, the elderly, and immunocompromised people. This falls within our focus area of scientific research.